Mass spectrometry platform could shrink cancer drug discovery cycle to four hours

Purdue researchers have unveiled a game-changing mass spectrometry platform that could shrink the notoriously slow cancer drug discovery cycle to a mere four hours, a dramatic acceleration from the typical days or weeks. Developed by the Purdue Institute for Cancer Research (PICR), this ultrahigh-throughput system integrates chemical synthesis, biological testing, and advanced mass spectrometry into a seamless, automated workflow, directly targeting one of the biggest bottlenecks in bringing new cancer therapies to patients. Traditionally, identifying promising drug compounds is a fragmented and labor-intensive process, involving disconnected steps from different teams, making it a 'fight against probability' to find the right molecules for tough cancer targets. This new platform, anchored by desorption electrospray ionization mass spectrometry (DESI-MS) pioneered at Purdue, directly addresses the inefficiency, allowing scientists like lead author Nicolás Morato and DESI-MS inventor R. Graham Cooks to rapidly generate, evaluate, and refine potential drug candidates within a single system. With cancer drug development often taking over a decade and facing significant costs, speeding up early-stage discovery is critical to combat the growing number of cancer targets identified through genomics and AI. The immediate impact of this platform means researchers can now rapidly screen tens of thousands of molecules, generating high-quality experimental data that will be crucial for refining and accelerating AI-driven drug discovery approaches. Andrew Mesecar, PICR's director, highlights that every year shaved off the development process translates to new drugs reaching patients faster and potentially extending lives. Moving forward, expect to see this integrated approach play a pivotal role in tackling difficult-to-drug cancer targets, pushing pharmaceutical innovation into a faster, more efficient era, and challenging the long-standing timelines of therapeutic development.